| |JULY 20269PATIENTS ADVOCACY CALLS FOR INCLUSION OF NEW CANCER DRUGS IN NLEMSUN PHARMA BAGS 12 MILLION WORTH DEAL WITH ORGANONUNREGISTERED IVF CLINICS MAY STRUGGLE UNDER NEW GOVERNMENT RULESHOW PHARMACEUTICALS CAN TRANSFORM ACCESS TO CANCER CARETELANGANA BOOSTS PHARMA STRENGTH WITH NEW CANCER DRUG PLANTThe patient advocacy groups in India called for the incorporation of new cancer drugs into the NLEM. This is due to an increasing disparity between medical developments and public health care provisions. The demand has been raised due to the lack of any revisions to the NLEM for about four years. Despite frequent revisions of such standards being set out by the WHO. The organizations claim that patients do not get access to vital and advanced medication due to the failure to revise and update the NLEM.The NLEM is responsible for regulating the prices of drugs and their availability in the country. Therefore, its revision becomes essential due to high numbers of cancer cases in India. This reform needs to be implemented immediately for the revision of the NLEM to incorporate modern medicines for cancers. PO The Indian corporate landscape has witnessed a major boost as Sun Pharmaceutical Industries announced its USD 11.75 billion acquisition of US-based Organon & India's Unregistered IVF Clinics could soon find it difficult to continue operations as the Centre has tightened IVF rules. The new rules are imposed to improve oversight of the country's growing fertility sector. The new move aims to ensure that only registered fertility clinics and ART banks can buy critical IVF supplies, bringing greater transparency and accountability. The decision is expected to strengthen patient trust while making it harder for unauthorized centers to operate outside the law. The latest directive comes from the Central Drugs Standard Control Organisation (CDSCO), which has instructed manufacturers and distributors to sell essential IVF laboratory products only to clinics and banks registered under the ART Act. The government believes this step will formalize the fertility sector without creating a major financial burden for patients seeking IVF treatment. POIndian healthcare sector transforms as pharmaceuticals step beyond traditional roles to make advanced treatments more accessible and affordable. High medical costs often become a barrier for patients, especially for critical illnesses like cancer. Therefore, collaborations between healthcare innovators and financial service providers emerge as a powerful solution to bridge the affordability gap.Cancer treatment, particularly advanced therapies, can cost between lakhs to over Rs 30 lakhs. That often becomes an immense financial strain Telangana has made another major move towards enhancing its pharmaceutical and healthcare manufacturing capability. By the latest launch of a highly advanced generic cancer drug manufacturing plant in Siddipet district of the state. The plant has been developed in the Biotech Park Phase-III in Karakapatla, Markook Mandal, and represents a big step forward for India in terms of oncology drugs manufacturing capability.This plant has been launched by the IT and Industries Minister, Duddilla Sridhar Babu, and established by the company Ciro Pharma Private Limited. It has been built through an investment of about Rs 800 crores. This has been described as the first ever integrated oncology manufacturing plant in India with the capability of producing several types of cancer treatment drugs. Such as oral oncology drugs, sterile injections, lyophilized powder injections, and soft gel capsules. POon families. Many patients delay or even abandon treatment due to the inability to arrange large upfront payments. Recognizing this challenge, companies are now introducing patient-centric financial solutions that allow individuals to focus on recovery rather than immediate financial burdens. POCo. This is marked as one of the largest overseas deals by an Indian company. This strategic move reshapes the global pharmaceutical space. It also pushes India's mergers and acquisitions (M&A) activity to a four-year high. That reflects in growing confidence among Indian firms in executing large-scale global transactions.The acquisition of Organon is seen as the biggest-ever buyout for any Indian pharmaceutical company, worth approximately USD 11.75 billion. This enables Sun Pharma to benefit from the already proven range of over 70 products in 140 countries. However, besides being a huge deal, the acquisition represents a new direction in the business of Sun Pharma from generics to innovative pharmaceuticals. PO
< Page 8 | Page 10 >